Home People Stavros Drakos – Biography, Age, Medical Education, Career & Net Worth

Stavros Drakos – Biography, Age, Medical Education, Career & Net Worth

Stavros Drakos (born 1971) is a board-certified American cardiologist in Salt Lake City, Utah. He subspecializes in interventional cardiology.

Drakos is the Medical Director, Cardiac Mechanical Support Program at the University of Utah Healthcare and School of Medicine in Salt Lake City.

Stavros Drakos

Stavros Drakos Facts

  • Full Name: Stavros George Drakos
  • Age: 52 years old
  • Date of Birth: 1971
  • Occupation: Cardiologist
  • Nationality: American

Stavros Drakos Medical School & Residency

  • University of Athens – Medical School

Arthur Agatston Career

Drakos is co-chief of the heart failure and transplant section and specializes in the treatment of patients suffering from heart failure, cardiomyopathies, heart transplantation, and mechanical circulatory support. His team is leveraging data gathered from both patient studies and heart failure models in order to comprehend and improve cardiac recovery.

Certifications & Licensure

  • UT State Medical License – Active through 2022

Hospital Affiliations

  • University Of Utah Hospitals And Clinics

Specialty Expertise

Dr. Stavros George Drakos has the following 14 areas of expertise

  • Acute Coronary Syndrome (ACS)
  • Stroke
  • High Cholesterol
  • Heart Attack
  • Unstable Angina
  • Blood Clot
  • Atherosclerosis
  • Heart Failure
  • High Cholesterol (Hypercholesterolemia)
  • Arrhythmia
  • High Blood Pressure (Hypertension)
  • Heart Diseases
  • Heart Block
  • Hypertension

Insurance Accepted

  • Aetna Choice POS II
  • Altius Provider Directory
  • BCBS Blue Card PPO
  • CIGNA HMO
  • CIGNA Open Access Plus
  • CIGNA PPO
  • First Health PPO
  • FocalPoint
  • Multiplan PPO
  • PHCS PPO
  • Regence Preferred – OR
  • Regence Preferred FocalPoint
  • UHC Options PPO

Location & Contact Information

University Of Utah Medical Group
50 N Medical Dr
Salt Lake City, UT 84132
(801) 581-7715

Fax: (801) 158-1773
Website: www.healthcare.utah.edu

University Of Utah Medical Group
50 N Medical Dr Clinic #10
Salt Lake City, UT 84132
(801) 585-5122

Fax:(801) 158-5231
Website:healthcare.utah.edu

University Of Utah School Of Medicine
30 N 1900 E
Salt Lake City, UT 84132

Fax:(801) 158-5330

University Of Utah Division Of Cardiology
30 N 1900 E
SALT LAKE CITY, UT 84132
(801) 585-7676

Fax:(307) 736-2957
Website:www.healthcare.utah.edu

Expert Publications

Data provided by the National Library of Medicine

  • Exacerbation of variant angina by metoprolol resulting in syncope due to transient atrioventricular block.
  • Effects of high doses versus standard doses of enalapril on endothelial cell function in patients with chronic congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy.
  • Moderate systemic hypotension during reperfusion reduces the coronary blood flow and increases the size of myocardial infarction in pigs.
  • Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone–an experimental study.
  • Myocardial ischaemic preconditioning in the pig has no effect on the ventricular fibrillation and defibrillation thresholds.
  • Comparison of pulsatile with nonpulsatile mechanical support in a porcine model of profound cardiogenic shock.
  • VE/VCO2 slope is associated with abnormal resting haemodynamics and is a predictor of long-term survival in chronic heart failure.
  • Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril.
  • Etiology of anemia in patients with advanced heart failure.
  • Ventricular-assist devices for the treatment of chronic heart failure.
  • Reverse remodeling during long-term mechanical unloading of the left ventricle.
  • HeartMate II left ventricular assist device; early European experience.
  • Increase in coronary blood flow by intra-aortic balloon counterpulsation in a porcine model of myocardial reperfusion.
  • Intra-aortic balloon counterpulsation and delayed revascularization for myocardial infarction and shock in the absence of primary angioplasty: a treatment strategy with or without thrombolysis?
  • Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy.

Clinical Trials

  • Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™
  • LVAD Conditioning for Cardiac Recovery

Stavros Drakos Net Worth

Stavros Drakos has an estimated net worth of $5 million.

Stavros Drakos Twitter

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.